Autologous stem cell transplantation for plasma cell disorders

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Abstract

Plasma cell disorders are diseases that result from an abnormal proliferation of a monoclonal population of plasma cells that may or may not secrete detectable levels of a monoclonal immunoglobulin or immunoglobulin fragment (paraprotein or M protein). The plasma cell disorders for which autologous stem cell transplant (ASCT) is a common treatment modality include multiple myeloma and AL amyloidosis. ASCT is a safe and effective treatment for both of these diseases and the types of patients who are eligible to undergo ASCT have expanded. ASCT remains a mainstay of therapy for multiple myeloma despite the advent of new treatments, and has shown improvement in overall survival especially when performed as a consolidative therapy after initial induction. Careful screening of patients with AL amyloidosis has increased the numbers of patients eligible for transplantation and improved outcomes for those patients.

Original languageEnglish
Title of host publicationOncology
Publisherwiley
Pages379-384
Number of pages6
ISBN (Electronic)9781119189596
ISBN (Print)9781119189558
DOIs
StatePublished - 30 Aug 2019

Keywords

  • AL amyloidosis
  • Autologous stem cell transplantation
  • Dialysis
  • Evidence-based clinical data
  • Mucositis
  • Multiple myeloma
  • Plasma cell disorders

Fingerprint

Dive into the research topics of 'Autologous stem cell transplantation for plasma cell disorders'. Together they form a unique fingerprint.

Cite this